3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Conditions
Thoracic Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Neoplasms, Nerve Tissue
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Lung Neoplasms
1
Lung Diseases
1
Head and Neck Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Medullary
1
Carcinoma, Bronchogenic
1
Carcinoma
1
Bronchial Diseases
1
Adenocarcinoma
1
Interventions
Cisplatin
47
Radiotherapy
37
Fluorouracil
23
Cetuximab
17
pembrolizumab
11
Carboplatin
11
Paclitaxel
8
Docetaxel
8
Radiotherapy, Intensity-Modulated
6
Chemotherapy, Adjuvant
6
Surgical Procedures, Operative
5
Standard of Care
5
nimotuzumab
4
Methotrexate
4
Gabapentin
4
Drug Therapy
4
Afatinib
4
Radiotherapy, Conformal
3
Radiation
3
Porfiromycin
3
Nivolumab
3
Neoadjuvant Therapy
3
Fibroblast Growth Factor 7
3
Bleomycin
3
zalutumumab
2
sargramostim
2
epacadostat
2
Tranexamic Acid
2
Tirapazamine
2
Pilocarpine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Head and Neck Neoplasms
×
pralsetinib
×
Clear all
NCT04222972
2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3
Terminated
223 enrolled
18 charts